NCT04281342已完成1 期
Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula (ΔΔQTcF)
研究概览
简要总结
To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic doses of aprocitentan do not have a clinically relevant effect on the QT interval.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Placebo-controlled.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
- •Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.
- •No clinically significant findings on the physical examination at screening.
- •Body mass index 18.0 to 30.0 kg/m2 (inclusive) at screening.
- •Systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 50-90 bpm (all inclusive), measured on the same arm, after 5 minutes in the supine position at screening.
- •12-lead safety ECG: QTcF less than 450 ms for male subjects and less than 470 ms for female subjects, QRS less than 110 ms, PR less than 220 ms, and resting HR greater than 50 bpm and less than 90 bpm with no clinically relevant abnormalities on 12-lead ECG after at least 5 min in the supine position at Screening and on Day 1 pre-dose of Period
- •No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry) at screening.
- •Negative results from urine drug screen, urine cotinine test, and breath alcohol tests at screening and on Day -1 of each period.
- •A woman of childbearing potential (WoCBP) is eligible only if the following applies:
- •Negative serum pregnancy test at screening.
- •Negative urine pregnancy test on Day -1 of each period.
- •Agreement to consistently and correctly use a highly effective method of contraception from screening up to at least 30 days after last study treatment administration in the last period with in-between periods included.
- •Women of non-childbearing potential (WoNCBP) must meet at least one of the following criteria:
- •Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy,
- •Confirmed premature ovarian failure,
- •Post-menopausal.
排除标准
- •Pregnant or lactating women.
- •Previous exposure to aprocitentan or macitentan.
- •Known hypersensitivity to aprocitentan or macitentan or any of the drug product excipients, or treatments of the same class.
- •Any contraindication or known hypersensitivity to moxifloxacin or any of the drug product excipients or to other fluoroquinolone antibiotics.
- •Known hypersensitivity or allergy to natural rubber latex.
- •History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
- •Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the study.
- •Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 2 weeks or 5 t½ (whichever is longer) prior to first study treatment administration with the exception of contraceptives in female subjects.
- •History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) or hypokalemia.
- •Legal incapacity or limited legal capacity at screening.
研究组 & 干预措施
Aprocitentan 25 mg
Experimental
Therapeutic dose level
干预措施: Aprocitentan 25 mg (Drug)
Aprocitentan 100 mg
Experimental
Supratherapeutic dose level
干预措施: Aprocitentan 100 mg (Drug)
Matching placebo
Placebo Comparator
干预措施: Matching placebo (Drug)
Moxifloxacin
Other
干预措施: Moxifloxacin control to establish assay sensitivity (Other)
结局指标
主要结局
Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula (ΔΔQTcF)
时间窗: Multiple predefined time points related to study treatment administration on Day 1 and Day 10 to 11 of each treatment.
次要结局
- Aprocitentan trough plasma concentrations (Ctrough)(Day 2 to Day 9)
- Aprocitentan plasma Cmax, first dose(Pre-defined times on the first dosing day (Day 1) up to 15 hours after last dose)
- Aprocitentan attainment of steady-state conditions(Day 1 to Day 10)
- Accumulation index between the first and the last dosing day of aprocitentan(Day 1; Day 10)
- Aprocitentan plasma Cmax, steady state(Pre-defined times on the last dosing day (Day 10) up to 15 hours after last dose)
- Area under the plasma concentration-time curve (AUCτ) during a dosage interval (τ) of aprocitentan(Day 1 to Day 10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia DisorderInsomniaNCT05423717Idorsia Pharmaceuticals Ltd.166
已完成
1 期
Japanese Phase 1 Multiple Ascending Dose (MAD) StudyDepressionNCT01396252Bristol-Myers Squibb57
已完成
1 期
PAC-14028 in Healthy Male VolunteersHealthyNCT01264224Amorepacific Corporation60
已完成
1 期
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary Disease (COPD)NCT00545311Novartis40
已完成
1 期
Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsHealthyNCT01916850Lexicon Pharmaceuticals25